Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by BioTeckon Jun 01, 2021 2:47pm
134 Views
Post# 33304326

RE:RE:RE:RE:any thoughts

RE:RE:RE:RE:any thoughtsFrom what I understand the top-up is part of the clinical trial protocol. Until they get their dosing right, they will continue doing top-ups. Picture it from a patients POV. WOuld you want to go on the immunosuppressants and all this trouble if you didn't know if the procedure would work or not? Because of this (IMO), they are ending the trial with portal vien so the trial candidates at least get that benefit at the end. Even 40 percent reduction of insulin is huge. Maybe when they dial in the correct dose, it could work even better. Remember these are patients with 0 insulin production. If they get the immuno tech down and are able to insert pouches into patients who are borderline or mild diabetics, it could potentially cure them.  
<< Previous
Bullboard Posts
Next >>